Midi Health vs Zealthy

Cons

• ✗Does NOT accept Medicare, Medicaid, or Medi-Cal — eliminates roughly 40% of the insured US adult population
• ✗GLP-1 prescribing is clinician-discretionary inside a broader menopause care plan, NOT a guaranteed offering at intake — readers signing up purely for GLP-1 access may not get it
• ✗Menopause-focused — not the right fit for men or younger women whose primary need is weight loss

Cons

• ✗TWO FDA warning letters for false/misleading marketing of compounded GLP-1s (Feb 2026 letter 717987 verified at fda.gov; September 2025 letter from secondary sources)
• ✗Active Novo Nordisk false-advertising lawsuit: Novo Nordisk A/S et al v. Zealthy Inc., case 1:25-cv-06391 (S.D.N.Y., filed 2025-08-04), alleging trademark infringement and marketing of compounded products as 'FDA-approved alternatives'
• ✗Active DOJ/FTC enforcement: United States v. Cerebral, Inc. et al, case 1:24-cv-21376 (S.D. Fla., amended complaint adding Zealthy Inc., Gronk Inc., founder Kyle Robertson, and others), alleging ROSCA violations (failure to disclose subscription terms, no informed consent for billing, locked cancellation), and unauthorized health-data sharing for targeted advertising
• ✗Founder pattern of conduct: Kyle Robertson previously founded Cerebral, which settled with the FTC in June 2024 ($5M consumer redress + $10M civil penalty suspended to $2M) for similar deceptive practices. Robertson then founded Zealthy and is alleged to have continued the same conduct
• ✗Company recently renamed FitRX/Zealthy to Gronk Inc. — rebrand pattern is itself a concerning signal in the context of active enforcement
• ✗Continued marketing of compounded semaglutide after FDA removed it from the shortage list on 2025-02-21 (post-shortage compounding without legal authorization)
• ✗Adds a $135/month membership fee on top of medication cost — total cash price is $286-$351/month
• ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option